Research

Pharmaceuticals
Biotech

Electra Therapeutics doses first patient in ipsoprubart T cell trial

Electra's SIRP-targeting monoclonal antibody enters a dedicated Phase 1 study in T cell malignancies, supported by a 100% tumour response rate in a
Electra's SIRP-targeting monoclonal antibody enters a dedicated Phase 1 study in T cell malignancies, supported by a 100% tumour response rate in a
The Biotech Times Editorial Team  · 
Diagnostics

Eupraxia EoE drug shows >90% inflammation cut in Phase 1b/2a data

EP-104GI reduced EoEHSS inflammation scores by more than 90% at the highest dose tested, with fibrosis improvements sustained to 36 weeks.
EP-104GI reduced EoEHSS inflammation scores by more than 90% at the highest dose tested, with fibrosis improvements sustained to 36 weeks.
The Biotech Times Editorial Team  · 
Diagnostics

Glucotrack CBGM hits 6.8% MARD over 240 days in ovine study

A peer-reviewed ovine study shows Glucotrack's implantable glucose monitor maintained accuracy for up to 240 days with no device-related adverse events.
A peer-reviewed ovine study shows Glucotrack's implantable glucose monitor maintained accuracy for up to 240 days with no device-related adverse events.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy

IN8bio to present GBM clinical data and TCE platform at ASCO and R&D Day

IN8bio will showcase its gamma-delta T cell engager platform and new glioblastoma clinical data across four conferences in May and June 2026.
IN8bio will showcase its gamma-delta T cell engager platform and new glioblastoma clinical data across four conferences in May and June 2026.
The Biotech Times Editorial Team  · 
Biotech

Kymera Therapeutics unveils KT-579 IBD preclinical data at DDW

Kymera's oral IRF5 degrader matched or outperformed JAK inhibitors and biologics in a preclinical IBD model; Phase 1 human data are due in the
Kymera's oral IRF5 degrader matched or outperformed JAK inhibitors and biologics in a preclinical IBD model; Phase 1 human data are due in the
The Biotech Times Editorial Team  · 
Genomics
Biotech

Madrigal licenses Arrowhead's PNPLA3 siRNA for $1bn in MASH push

Madrigal Pharmaceuticals has licensed ARO-PNPLA3 from Arrowhead, targeting a common genetic driver of MASH prevalent in Hispanic patients.
Madrigal Pharmaceuticals has licensed ARO-PNPLA3 from Arrowhead, targeting a common genetic driver of MASH prevalent in Hispanic patients.
The Biotech Times Editorial Team  · 
Regulatory Science

Cytokinetics' aficamten hits dual Phase 3 endpoints in nHCM

ACACIA-HCM met both primary endpoints — symptom burden and exercise capacity — marking the first positive Phase 3 trial in non-obstructive HCM.
ACACIA-HCM met both primary endpoints — symptom burden and exercise capacity — marking the first positive Phase 3 trial in non-obstructive HCM.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Pharmaceuticals

Tempest Therapeutics to present TPST-2003 CAR-T data at ISCT 2026

Tempest will share updated REDEEM-1 Phase 1/2a results for its CD19/BCMA dual-targeting CAR-T in relapsed/refractory myeloma at Dublin's
Tempest will share updated REDEEM-1 Phase 1/2a results for its CD19/BCMA dual-targeting CAR-T in relapsed/refractory myeloma at Dublin's
The Biotech Times Editorial Team  · 
Pharmaceuticals
Genomics

Annovis Bio publishes Phase 2/3 buntanetap Alzheimer's data in Nature

Peer-reviewed results show buntanetap improved cognition in pTau217-positive early AD patients, with biomarker reductions suggesting potential disease-modifying activity.
Peer-reviewed results show buntanetap improved cognition in pTau217-positive early AD patients, with biomarker reductions suggesting potential disease-modifying activity.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Regulatory Science

Creative Medical claims 93% response rate in Ultrasome knee OA pilot

CELZ reported its cell-free Ultrasome therapy met its primary endpoint in a knee osteoarthritis pilot, with no serious adverse events observed.
CELZ reported its cell-free Ultrasome therapy met its primary endpoint in a knee osteoarthritis pilot, with no serious adverse events observed.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Cristcot to present CESSA corticosteroid data at DDW 2026

Cristcot will present Phase 3 ulcerative colitis trial data on covert steroid use at Digestive Disease Week in Chicago on 5 May.
Cristcot will present Phase 3 ulcerative colitis trial data on covert steroid use at Digestive Disease Week in Chicago on 5 May.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Greenwich LifeSciences delays 10-K amid FLAMINGO-01 data update

Greenwich LifeSciences has pushed its 2025 annual filing to May while reporting a 70–80% recurrence reduction in preliminary Phase III open-label data.
Greenwich LifeSciences has pushed its 2025 annual filing to May while reporting a 70–80% recurrence reduction in preliminary Phase III open-label data.
The Biotech Times Editorial Team  · 
Pharmaceuticals

InnoCare doses first patient in Phase III orelabrutinib SLE trial

InnoCare has initiated a registrational Phase III study of its BTK inhibitor orelabrutinib in SLE, backed by promising Phase IIb data showing a 57% SRI

The Phase III study is a randomised, double-blind, placebo-controlled, multicentre design. The primary endpoint is the SLE Response Index-4 (SRI-4) response rate at Week 52 — the same validated composite measure used in the preceding Phase IIb programme.

InnoCare's confidence in advancing to Phase III rests on a Phase IIb readout in which orelabrutinib 75 mg once daily produced a statistically significant improvement in SRI-4 response versus placebo at Week 48, recording rates of 57.1% against 34.4% (p < 0.05). The results were achieved under stringent steroid-tapering requirements, which the company argues makes the signal more clinically meaningful than comparisons in which corticosteroid use was unrestricted.

The Biotech Times Editorial Team  · 
Pharmaceuticals

Telix OPTIMAL-PSMA dosimetry data back TLX597-Tx dose push

Phase 2 data presented at IPCS 2026 show low off-target radiation, supporting dose intensification and a new mHSPC trial for Telix's next-generation
Phase 2 data presented at IPCS 2026 show low off-target radiation, supporting dose intensification and a new mHSPC trial for Telix's next-generation
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Quoin Pharma lines up four QRX009 rapamycin studies for 2026

Quoin Pharmaceuticals is launching investigator-led trials of its topical rapamycin in three rare skin diseases and plans a first IND filing by Q3 2026.
Quoin Pharmaceuticals is launching investigator-led trials of its topical rapamycin in three rare skin diseases and plans a first IND filing by Q3 2026.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Rein Therapeutics enrolls first patients in Phase 2 IPF trial

Eight patients are now enrolled in the RENEW study of inhaled peptide LTI-03, with sites active in the US, Australia, and Poland.
Eight patients are now enrolled in the RENEW study of inhaled peptide LTI-03, with sites active in the US, Australia, and Poland.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Medical Devices

Syncromune presents SYNC-T Phase 1 data at ECIO 2026

The Fort Lauderdale biotech reported an 87% overall response rate in a 15-patient Phase 1 study and is advancing to Phase 2 in metastatic
The Fort Lauderdale biotech reported an 87% overall response rate in a 15-patient Phase 1 study and is advancing to Phase 2 in metastatic
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Tonix Pharmaceuticals presents Phase 1 data for Lyme mAb TNX-4800

Tonix plans an adaptive Phase 2 field study of its anti-OspA monoclonal antibody in 2027, targeting a prevention gap with no approved U.S
Tonix plans an adaptive Phase 2 field study of its anti-OspA monoclonal antibody in 2027, targeting a prevention gap with no approved U.S
The Biotech Times Editorial Team  · 
Pharmaceuticals

Zealand Pharma and Roche to start petrelintide Phase 3 in H2 2026

The Copenhagen biotech and its Roche partner will advance their once-weekly amylin analog into Phase 3 obesity trials after Phase 2 showed double-digit
The Copenhagen biotech and its Roche partner will advance their once-weekly amylin analog into Phase 3 obesity trials after Phase 2 showed double-digit
The Biotech Times Editorial Team  · 
Digital Health

KFSH Named Saudi Arabia's Most Valuable Healthcare Brand

King Faisal Specialist Hospital and Research Centre (KFSH) has been named Saudi Arabia & the Middle East’s Most Valuable Healthcare Brand for the fourth consecutive year

King Faisal Specialist Hospital and Research Centre (KFSH) has been named Saudi Arabia and the Middle East’s Most Valuable Healthcare Brand for the fourth consecutive year, with its brand value surpassing USD 1.7 billion (SAR 6.3 billion), according to Brand Finance’s 2026 ran

The Biotech Times Editorial Team  · 
Subscribe to Research